Sterile Bioprocess Filtration Market Global Report 2026

The sterile bioprocess filtration market size has grown exponentially in recent years. It will grow from $4.59 billion in 2025 to $5.53 billion in 2026 at a compound annual growth rate (CAGR) of 20.6%. The growth in the historic period can be attributed to traditional batch based bioprocessing methods, limited adoption of high efficiency sterile filtration systems, rising demand for biologics and vaccines, expansion of pharmaceutical manufacturing infrastructure, increasing regulatory focus on product sterility and safety.

The sterile bioprocess filtration market size is expected to see exponential growth in the next few years. It will grow to $11.52 billion in 2030 at a compound annual growth rate (CAGR) of 20.1%. The growth in the forecast period can be attributed to growth in cell and gene therapy manufacturing demand, increasing adoption of single use and disposable filtration systems, rising integration of automated bioprocessing technologies, expansion of biologics pipeline and contract manufacturing, stricter global regulatory standards for sterile production. Major trends in the forecast period include single use sterile filtration systems adoption in bioprocessing workflows, high throughput membrane filtration for biologics purification, advanced aseptic fill finish filtration integration in pharma manufacturing, continuous bioprocess filtration for scalable biologics production, automated filter integrity testing and validation systems in sterile processing.

The rising demand for biopharmaceuticals is expected to drive the growth of the sterile bioprocess filtration market going forward. Biopharmaceuticals are therapeutic products developed from biological sources, including monoclonal antibodies, vaccines, recombinant proteins, and biosimilars. The demand for biopharmaceuticals is increasing due to the rising burden of chronic diseases and the growing adoption of targeted biologic therapies. Sterile bioprocess filtration plays a crucial role in biopharmaceutical manufacturing by ensuring contamination control, maintaining product purity, and enabling efficient downstream processing. For instance, in January 2025, according to the U.S. Food and Drug Administration (FDA), a US-based federal regulatory agency, the Center for Drug Evaluation and Research (CDER) approved a record 18 biosimilars across 8 reference products in 2024, marking the highest annual approval total achieved to date. Therefore, the increasing demand for biopharmaceuticals is driving the growth of the sterile bioprocess filtration market.

Major companies operating in the sterile bioprocess filtration market are focusing on developing advanced solutions, such as virus removal filters, to strengthen contamination control, improve biologic safety, and enable efficient biopharmaceutical manufacturing operations. Virus removal filters refer to specialized filtration technologies developed to remove viral contaminants from biologic products while maintaining high process efficiency, product integrity, and manufacturing performance. For instance, in October 2024, Asahi Kasei Medical Co. Ltd., a Japan-based medical device and bioprocess solutions company, introduced Planova FG1, a next-generation virus removal filter for biopharmaceutical manufacturing. The advanced filtration solution is designed to provide higher filtration flux, reliable viral clearance performance, and compatibility with sterilization-in-place (SIP) processes. It supports improved process efficiency and dependable contamination control in biologics production, helping manufacturers fulfill strict safety and scalability requirements in biopharmaceutical processing.

In September 2025, Thermo Fisher Scientific Inc., a US-based life sciences and laboratory products company, acquired Solventum’s Purification and Filtration business for an undisclosed amount. Through this acquisition, Thermo Fisher Scientific Inc. aims to enhance its purification and filtration capabilities by incorporating Solventum’s technologies and expanding its portfolio of solutions that support sterile and high-efficiency biologics manufacturing. Solventum is a US-based healthcare company that provides purification and filtration solutions for biopharmaceutical and life sciences applications.

Major companies operating in the sterile bioprocess filtration market report are Compagnie de Saint-Gobain S.A., Thermo Fisher Scientific Inc., 3M Company, Danaher Corporation, Merck KGaA, Parker-Hannifin Corporation, Asahi Kasei Corporation, Sartorius AG, Donaldson Company Inc., Repligen Corporation, GVS S.p.A., Porvair plc, Meissner Filtration Products Inc., Antylia Scientific Inc., Ami Polymer Private Limited, DrM Dr. Mueller AG, Amazon Filters Ltd., FILTROX AG, Hangzhou Cobetter Filtration Equipment Co. Ltd., Sterlitech Corporation, Eaton Corporation, Filtration Group Corporation, Graver Technologies.

North America was the dominating region in the sterile bioprocess filtration market in 2025. Asia-Pacific is expected to be the rapidly growing region in the forecast period. The regions covered in the sterile bioprocess filtration market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the sterile bioprocess filtration market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

This product will be delivered within 3-5 business days.